Cargando…
Toward Drug-Like Multispecific Antibodies by Design
The success of antibody therapeutics is strongly influenced by their multifunctional nature that couples antigen recognition mediated by their variable regions with effector functions and half-life extension mediated by a subset of their constant regions. Nevertheless, the monospecific IgG format is...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589779/ https://www.ncbi.nlm.nih.gov/pubmed/33053650 http://dx.doi.org/10.3390/ijms21207496 |
_version_ | 1783600657660379136 |
---|---|
author | Sawant, Manali S. Streu, Craig N. Wu, Lina Tessier, Peter M. |
author_facet | Sawant, Manali S. Streu, Craig N. Wu, Lina Tessier, Peter M. |
author_sort | Sawant, Manali S. |
collection | PubMed |
description | The success of antibody therapeutics is strongly influenced by their multifunctional nature that couples antigen recognition mediated by their variable regions with effector functions and half-life extension mediated by a subset of their constant regions. Nevertheless, the monospecific IgG format is not optimal for many therapeutic applications, and this has led to the design of a vast number of unique multispecific antibody formats that enable targeting of multiple antigens or multiple epitopes on the same antigen. Despite the diversity of these formats, a common challenge in generating multispecific antibodies is that they display suboptimal physical and chemical properties relative to conventional IgGs and are more difficult to develop into therapeutics. Here we review advances in the design and engineering of multispecific antibodies with drug-like properties, including favorable stability, solubility, viscosity, specificity and pharmacokinetic properties. We also highlight emerging experimental and computational methods for improving the next generation of multispecific antibodies, as well as their constituent antibody fragments, with natural IgG-like properties. Finally, we identify several outstanding challenges that need to be addressed to increase the success of multispecific antibodies in the clinic. |
format | Online Article Text |
id | pubmed-7589779 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75897792020-10-29 Toward Drug-Like Multispecific Antibodies by Design Sawant, Manali S. Streu, Craig N. Wu, Lina Tessier, Peter M. Int J Mol Sci Review The success of antibody therapeutics is strongly influenced by their multifunctional nature that couples antigen recognition mediated by their variable regions with effector functions and half-life extension mediated by a subset of their constant regions. Nevertheless, the monospecific IgG format is not optimal for many therapeutic applications, and this has led to the design of a vast number of unique multispecific antibody formats that enable targeting of multiple antigens or multiple epitopes on the same antigen. Despite the diversity of these formats, a common challenge in generating multispecific antibodies is that they display suboptimal physical and chemical properties relative to conventional IgGs and are more difficult to develop into therapeutics. Here we review advances in the design and engineering of multispecific antibodies with drug-like properties, including favorable stability, solubility, viscosity, specificity and pharmacokinetic properties. We also highlight emerging experimental and computational methods for improving the next generation of multispecific antibodies, as well as their constituent antibody fragments, with natural IgG-like properties. Finally, we identify several outstanding challenges that need to be addressed to increase the success of multispecific antibodies in the clinic. MDPI 2020-10-12 /pmc/articles/PMC7589779/ /pubmed/33053650 http://dx.doi.org/10.3390/ijms21207496 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Sawant, Manali S. Streu, Craig N. Wu, Lina Tessier, Peter M. Toward Drug-Like Multispecific Antibodies by Design |
title | Toward Drug-Like Multispecific Antibodies by Design |
title_full | Toward Drug-Like Multispecific Antibodies by Design |
title_fullStr | Toward Drug-Like Multispecific Antibodies by Design |
title_full_unstemmed | Toward Drug-Like Multispecific Antibodies by Design |
title_short | Toward Drug-Like Multispecific Antibodies by Design |
title_sort | toward drug-like multispecific antibodies by design |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589779/ https://www.ncbi.nlm.nih.gov/pubmed/33053650 http://dx.doi.org/10.3390/ijms21207496 |
work_keys_str_mv | AT sawantmanalis towarddruglikemultispecificantibodiesbydesign AT streucraign towarddruglikemultispecificantibodiesbydesign AT wulina towarddruglikemultispecificantibodiesbydesign AT tessierpeterm towarddruglikemultispecificantibodiesbydesign |